南京海辰药业

Nanjing Haichen Pharmaceutical is a prominent Chinese pharmaceutical company dedicated to the research, development, and manufacturing of high-quality chemical drugs. Founded in 2003 and headquartered in Nanjing, the company has built a diverse portfolio focusing on cardiovascular, anti-infective, digestive, and endocrine therapeutic areas. Its commercial success is driven by key products such as injectable Ginkgo Biloba extract and a range of cephalosporin antibiotics and proton pump inhibitors. Haichen Pharmaceutical operates state-of-the-art manufacturing facilities that comply with national GMP standards, ensuring the production of both active pharmaceutical ingredients and finished dosage forms. The company is publicly listed on the Shenzhen Stock Exchange and continues to transition from a generic-focused manufacturer to an innovation-driven enterprise. With a robust R&D pipeline including Class 1 innovative drugs, Haichen is well-positioned to address evolving healthcare needs in the Chinese market.